P&R brief France: What the latest updates mean for pharma pricing and market access
Published on March 24, 2025
Explore the key implications of the 2025 LFSS and the latest CEPS annual report on the French drug and medical device pricing and market access environment.
The 2025 LFSS (annual Social Security Financing Law) and the latest CEPS annual activity report published in February 2025 and December 2024, respectively, provide insights into the changing French P&MA environment.
What are the key learnings from the latest CEPS report focusing on 2023?
In 2023, litigation surged, drug price increase requests spiked, and savings from price reductions remained flat. Meanwhile, the fast-track program continued to attract little attention, and key rebate data remains pending until Q1 2025.